HBB rs121908249: Understanding the Hb C-Harlem Variant
The rs121908249 variant in the HBB gene is a complex genetic alteration known as Hb C-Harlem. It is associated with hemoglobin disorders that can mimic the clinical presentation of sickle-beta-thalassemia.
What each genotype means
Typical hemoglobin beta sequence
You carry two copies of the common wild-type allele at this genomic position. This genotype does not encode the double-mutation variant responsible for Hemoglobin C-Harlem. Your hemoglobin beta chain sequence is typical at this site.
Carried by more than 99% of individuals across all major global populations.
Hemoglobin C-Harlem carrier
You carry one copy of the variant allele associated with Hemoglobin C-Harlem, a complex beta-globin variant. In research literature, carriers are typically asymptomatic but may produce an altered hemoglobin molecule that migrates like HbC and can polymerize under hypoxia. Co-inheritance with other beta-globin variants or traits can modify hematologic presentation, and genetic findings should be discussed with a healthcare provider.
Extremely rare globally, identified almost exclusively at very low frequencies in individuals of African ancestry.
Homozygous Hemoglobin C-Harlem
You carry two copies of the variant allele encoding Hemoglobin C-Harlem. Homozygosity for this altered beta-globin chain is documented to cause sickling and hemolytic manifestations akin to sickle-beta-thalassemia spectrum disorders. Individuals with this finding typically require specialized hematology consultation for clinical and laboratory evaluation.
Exceptionally rare worldwide, documented only in isolated case reports primarily among individuals of African descent.
What is rs121908249?
The variant rs121908249, commonly referred to as Hb C-Harlem, is a specific genetic change located within the HBB gene on chromosome 11. Unlike simple single-nucleotide polymorphisms that involve a single letter change, this variant involves a more complex alteration in the DNA sequence. It is categorized as a pathogenic variant in clinical databases because it affects the structure and function of the beta-globin protein. Because it sits within the coding region of the HBB gene, it directly influences the production of hemoglobin, the essential protein in red blood cells responsible for transporting oxygen throughout the body. Understanding this variant requires looking at how it alters the amino acid sequence of the beta-globin chain, which in turn changes the physical properties of the hemoglobin molecule itself.
The Role of the HBB Gene
The HBB gene provides instructions for making a protein called beta-globin. This protein is a vital component of hemoglobin, the iron-containing molecule in red blood cells that binds to oxygen in the lungs and delivers it to tissues throughout the body. Hemoglobin is typically composed of two alpha-globin subunits and two beta-globin subunits. When the HBB gene contains a pathogenic variant, the resulting beta-globin protein may be unstable, produced in insufficient quantities, or structurally abnormal. These changes can lead to a group of disorders known as hemoglobinopathies. In the case of Hb C-Harlem, the structural change can cause red blood cells to behave abnormally, potentially leading to chronic hemolysis, where red blood cells are destroyed faster than the body can replace them, or other hematological complications.
Clinical Associations and Evidence
Research associates the rs121908249 variant with hemoglobin disorders that share clinical features with sickle-beta-thalassemia. The evidence for this association is considered strong within the clinical genetics community, as the variant is known to produce an abnormal hemoglobin variant that can be detected via specialized blood testing, such as electrophoresis or high-performance liquid chromatography. Because this variant can be inherited alongside other HBB mutations, individuals may present with compound heterozygous conditions, where the interaction between two different HBB variants dictates the severity of the clinical phenotype. It is important to note that the presence of this variant does not automatically guarantee a specific health outcome, as clinical expression can be influenced by other genetic factors and environmental modifiers. Clinical diagnostic laboratories classify this as a pathogenic variant due to its documented impact on hemoglobin function.
Population Frequency
The rs121908249 variant is rare in the general global population. It is primarily identified in individuals of African descent. Because it is a rare variant, it is not typically included in standard, broad-spectrum carrier screening panels unless specifically requested or indicated by family history or clinical symptoms. Its distribution is consistent with other hemoglobin variants that have historically provided a selective advantage in regions where malaria is endemic, though the specific evolutionary history of Hb C-Harlem is distinct from the more common Hb S (sickle cell) variant. Due to its rarity, population-wide frequency data is limited, and most documented cases arise from clinical diagnostic settings where individuals are being evaluated for unexplained anemia or abnormal hemoglobin findings on routine blood work.
Managing Genetic Information
Information regarding the rs121908249 variant is intended for educational purposes and should not be used for self-diagnosis or medical decision-making. If you have received a report indicating the presence of this variant, it is essential to discuss the findings with a qualified healthcare provider, such as a hematologist or a genetic counselor. They can provide context based on your personal and family medical history, interpret the results in light of other potential genetic modifiers, and discuss appropriate clinical management or monitoring. You cannot change your genetic sequence, but understanding your carrier status or genotype can be valuable for family planning and personalized medical care. Always rely on professional clinical guidance rather than online databases when interpreting genetic test results, as the clinical significance of any variant depends heavily on the individual's overall genetic and health context.
How common is this variant?
The rs121908249 variant is rare in the general population and is primarily found in individuals of African descent.
Frequently asked questions
What is Hb C-Harlem?
Hb C-Harlem is a specific, rare variant of the HBB gene. It results in the production of an abnormal hemoglobin protein that can lead to blood disorders similar to sickle-beta-thalassemia.
Is Hb C-Harlem the same as sickle cell disease?
No, they are different. While both involve the HBB gene and affect hemoglobin, they are caused by different mutations. However, they can both lead to similar types of red blood cell complications.
How is this variant detected?
This variant is typically detected through specialized blood tests like hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). Genetic testing can also confirm the presence of the specific DNA mutation.
Should I be tested for this variant?
Testing is generally recommended only if you have a family history of hemoglobin disorders or if a doctor suspects a hemoglobinopathy based on blood test results. Consult with a genetic counselor or hematologist to determine if testing is appropriate for you.
Sources & further reading
Educational information only, last refreshed 10/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908249?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in HBB
This variant is a pathogenic mutation in the HBB gene associated with beta-thalassemia.
This variant is a pathogenic mutation in the HBB gene associated with hemoglobinopathies such as sickle cell disease.
This variant (c.20A>T, p.Glu7Val) causes the substitution of valine for glutamic acid in the beta-globin chain, leading to sickle cell trait or disease depending on zygosity.
Pathogenic variant (p.Glu6Val, HbS-Antilles) in HBB associated with sickle cell disease-like pathology.
Pathogenic nonsense mutation (c.118C>T / p.Gln40Ter / codon 39 nonsense) causing beta-zero thalassemia and classic carrier status (beta-thalassemia minor).
A variant in the HBB gene linked to beta-thalassemia carrier status.